News

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme’s ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer

Approval extends RYBREVANT FASPRO’s well-established, dual-targeted benefit beyond lung cancer SAN DIEGO, Nov. 6, 2026 /PRNewswire/ — Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced that Johnson & Johnson was granted accelerated approval from the […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Onchilles Pharma Reports First Clinical Data at SITC 2026 That N17350 Could Turn One Tumor into a Personalized Cancer Vaccine

SAN DIEGO–(BUSINESS WIRE)– #ELANE–Onchilles Pharma Reports First Clinical Data at SITC 2026 That N17350 Could Turn One Tumor into a Personalized Cancer Vaccine Click here to view original post Click Here to Publish/Feature Your Company […]

No Picture
News

Arima Genomics to Showcase Expanding Clinical Reach of Aventa FusionPlus and Aventa Lymphoma at AMP 2026

CARLSBAD, Calif.–(BUSINESS WIRE)–Arima Genomics, Inc., a cancer diagnostics company bringing DNA sequence and structure together to advance cancer diagnosis and therapy selection, today announced its participation in the Association for Molecular Pathology (AMP) 2026 Annual […]


ADVERTISEMENT — Advertise With Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks
News

Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress

SAN DIEGO, Nov. 3, 2026 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its participation in the 2026 Neuroscience Education Institute (NEI) Fall Congress, taking place Nov. 5-8 in Colorado Springs, Colo. Through a […]

News

TCT26: Medtronic Symplicity blood pressure procedure shows significant blood pressure drops in SPYRAL AFFIRM real-world study

Nearly nine out of 10 patients experienced a clinical benefit at six months Medtronic receives FDA approval for U.S. labeling update to Symplicity blood pressure procedure, expanding clinical evidence informing treatment options GALWAY, Ireland and […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

ELUCIDATE Study Demonstrates 93 Percent Accuracy with Strong Performance in the “Gray Zone” for Elucid’s FDA-cleared FFR-IQ™

BOSTON & SAN DIEGO–(BUSINESS WIRE)– #CCTA–Elucid, an innovator of AI-powered cardiovascular imaging software, today announced results from ELUCIDATE, presented at the annual Transcatheter Cardiovascular Therapeutics Conference (TCT 2026). The ELUCIDATE study, which supported Elucid’s recent […]


ADVERTISEMENT — Advertise With Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints

Both post-implant monotherapies in the trial achieved non-inferiority compared to dual anti-platelet therapy (DAPT) supporting the potential to simplify post-procedure drug regimens MARLBOROUGH, Mass. and SAN DIEGO, Nov. 2, 2026 /PRNewswire/ — Boston Scientific Corporation […]


ADVERTISEMENT — Advertise With Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks
News

Paulex Bio Announces Registration of Phase 1/2a Trial of PAL-119, an Oral Small Molecule Designed to Regenerate and Restore the Function of Insulin-Producing Beta Cells

First-in-human study plans to enroll healthy volunteers and adults with Type 1 or Type 2 diabetes to evaluate PAL-119’s safety and tolerability and explore its effects on the body’s own insulin production SAN DIEGO, Nov. […]

No Picture
News

Reflow Medical Reports One-Year Results from DEEPER CORONARY Study of Investigational Coronary Spur® Elute Sirolimus-Eluting Retrievable Stent System

SAN CLEMENTE, Calif.–(BUSINESS WIRE)– #TCT2026–Reflow Medical, Inc., a leading developer of innovative devices for treating complex cardiovascular disease, announces the presentation of one-year clinical results from the first-in-human DEEPER CORONARY study at Transcatheter Cardiovascular Therapeutics […]

No Picture
News

Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results

SAN DIEGO–(BUSINESS WIRE)– #PressRelease–Johnson & Johnson announced results from three clinical analyses being presented during the Transcatheter Cardiovascular Therapeutics annual scientific symposium (TCT 2026) that report positive survival and patient outcomes data when Impella™ heart […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Setara Biosciences Announces $90 Million Series A Financing to Advance Precision Medicines for Rare Genetic Diseases and Related Expansion Indications

SAN DIEGO–(BUSINESS WIRE)–Setara Biosciences, Inc. (Setara), a clinical-stage biotechnology company leveraging genetics to develop precision medicines for severe rare diseases, today announced the completion of a $90 million Series A financing. Setara was formed following […]